Open Book Extracts Launches Research Study On Minor Cannabinoids For Relaxation And Calmness

Open Book Extracts Launches Research Study On Minor Cannabinoids For Relaxation And Calmness

Open Book Extracts launched a placebo-controlled trial of minor cannabinoid formulations to improve relaxation and calmness.

The most prevalent mental health disorder in the world is anxiety. Globally, an estimated 284 million people experienced anxiety disorders in 2017, with women being diagnosed at twice the rate of men. To address this market need, OBX developed and tested distinct formulas designed to help people unwind (relaxation) and/or clear their mind (calmness).

Based on scientific literature and real-world anecdotal feedback, six active ingredients were selected and formulated to promote two distinct mood states: relaxation and calmness. The cannabinoids selected were CBD, CBG, CBC, and CBDV, and the polyphenols selected were Quercetin and Curcumin. The primary criteria for selecting candidates was evidence of anxiolytic-like effects with minimal sedative-like effects. Secondary criteria included alterations in mood, sleep, and/or cognitive performance.

A randomized, double-blinded, placebo-controlled evaluation is being conducted to determine the efficacy of these products. Self-reported outcomes will be collected and reported on relaxation and stress. The study will be virtual and with no in-person visits. A secure online software service will allow for anonymous tracking of the real-time experiences of study products.

"Too many people who are struggling with mental health issues also struggle with gaining access to effective, non-pharmaceutical solutions," stated Andrea Baillo, OBX chief scientific officer. "The OBX Relaxation Study will test distinct formulations of cannabinoids and other bioactives, to better understand their ability to improve relaxation, stress, and overall well-being."

Benzinga's Cannabis Capital Conference Is Back

The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference, returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now. Prices will surge very soon.

Photo by Tim Foster on Unsplash

Posted In: CannabisNewsMarketsAndrea BailloOpen Book Extractspremium


Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us April 11-12, 2023 at Fontainebleau Miami Beach in sunny Florida.